Medi-Caps Q1 Profit Slump Undermines Revenue Stability
The real estate developer posted a modest 3.7% yearly revenue gain, but profit fell sharply both year-on-year and quarter-on-quarter.
Medi-Caps reported a quarterly loss of ₹2.23 crore, a significant reversal from the profit of ₹3.04 crore in the previous quarter, despite a slight uptick in revenue.
Medi-Caps Limited's first-quarter earnings for FY27 reveal a challenging period, with profitability taking a severe hit despite a slight increase in revenue. The company reported a net loss of ₹2.23 crore, a sharp reversal from the ₹3.04 crore profit in the preceding quarter and a deeper loss than the same period last year.
Revenue for the quarter ended June 2026 came in at ₹2.79 crore, marking a 3.7% year-on-year increase. However, this top-line stability was overshadowed by a 36.1% year-on-year decline in profit. Sequentially, the picture is even starker, with revenue falling 19.1% from the March quarter and profit swinging into negative territory, representing a 173.4% quarterly drop. The trailing twelve-month (TTM) figures underscore persistent challenges, with a cumulative loss of ₹1.78 crore on revenue of ₹12.55 crore, resulting in a negative TTM net profit margin of -14.2%.
The company's recent quarterly performance has been volatile, as shown in the table below:
Revenue (₹ Cr)
Profit (₹ Cr)
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Period Ended | June 2026 | March 2026 | June 2025 |
| Revenue (₹ Cr) | 2.79YoY +3.7% | 3.45 | 2.69 |
| Profit (₹ Cr) | -2.23YoY +36% | 3.04 | -3.49 |
Key Points
- The company maintains a debt-free balance sheet with a debt-to-equity ratio of 0.0 and a strong current ratio of 17.34.
- However, key profitability metrics remain under pressure, with a negative Return on Equity (ROE) of -2.61% and a trailing twelve-month EPS of -₹2.44.
- The stock price has reflected these operational headwinds, declining 32.5% over the past year.
For a company in transition to real estate development, the latest quarterly loss highlights the ongoing execution hurdles in converting sporadic revenue into consistent bottom-line growth.
Live Chart
· MEDICAPQ
(BSE)
ISIN: INE442D01010
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.